24 November 2025 A regulatory counsel with nine years at the FDA and over two decades of patent experience has joined a firm in Washington, DC.
24 November 2025
21 November 2025
20 November 2025
20 November 2025
20 November 2025
Latest Features
Americas
The USPTO’s ‘settled expectations’ rule is anything but settled, argues Andrew Zappia of Troutman Pepper Locke.
Americas
Parties impacted by exclusion orders need to carefully weigh their options for seeking clarity or rulings on redesigns, explain Daniel Muino and Charles Provine from Morrison Foerster.
Europe
As Big Pharma stalls investment in the UK, the government urgently needs to return to the negotiating table to salvage a key growth area, writes Tim Belcher of EIP.
Americas
In the second of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax delve into the real reasons why medicine costs more in the US.
Americas
In the first of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax explore how legislative, judicial, and executive policies have dramatically altered the risks for drug innovation.
Biotechnology
Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.
Americas
With growing legislation, research and demand for medical use, cannabis presents an economic opportunity for the Caribbean—but IP rights in the region have some way to go, write Keesha Fleming Lake of Keesha Fleming Lake, and Rachael Lodge Corrie of Foga Daley.
Americas
From setting a clear overall strategy to drafting high-quality claims, Christopher Wheeler and Gerald Murphy of Birch, Stewart, Kolasch & Birch explain how to reduce patent prosecution expenditure and obtain better IP protection.
Latest Conference Videos
Unified Patent Court
Powell Gilbert experts share insights on how the Unified Patent Court is taking shape after two years in operation, in this session from LSPN.
Americas
This LSPN panel brings together experts from Troutman Pepper Locke, Sauvegarder Investment Management, Beam Therapeutics, Editas Med, and Takeda to explore the expanding role of IP lawyers in the life sciences industry.
Americas
Jennifer Che of Eagle IP explores key IP challenges in China and offers practical strategies to address them, covering topics such as AI, patent linkage and export controls in this LSPN session.
Americas
This LSPN session features experts from EIP, The Broad Institute of MIT and Harvard, Pfizer, and an independent specialist discussing the protection of life science innovations involving big data, AI, and machine learning.
More News
19 November 2025 The court rules that Duke University and Allergan’s patent lacked sufficient written description, in the wake of stricter post-Amgen Section 112 standards.
18 November 2025 The combination will create a firm with 3,000 lawyers across 52 offices—but a dive into its combined IP practice shows a heavy weighting in the US.
18 November 2025 An EUIPO appeals board sided with the French pharma company’s vaccine division in a dispute with an India-based biotech company over Sanofi’s ‘Covaxis’ mark.
18 November 2025 With “deep connections” in the US and Asia and life sciences patents in his name, the new partner joins the firm at a time of IP practice expansion.
17 November 2025 A federal jury finds Apple infringed Masimo’s pulse oximetry patent, while the ITC has opened a new proceeding to review Apple's redesigned smartwatch.
14 November 2025 In-house counsel from AstraZeneca, BAT and Novartis say that investing in AI now will pay off in time saved, but warn that tools remain prone to ‘confident’ errors, writes Marisa Woutersen.
13 November 2025 Inconsistent Bolar interpretations and tougher trial disclosures are tightening the squeeze on innovators in life sciences, counsel told LSPN Europe. Tom Phillips reports.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox